CD30 in hodgkin lymphoma
4 EU-approved indications in hodgkin lymphoma need a CD30 result: brentuximab vedotin (1st line, advanced), brentuximab vedotin (1st line, advanced), brentuximab vedotin (consolidation) and brentuximab vedotin (3rd line+).
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CD30-positive4 | ||||
Adcetris | CD30+ | + doxorubicin, vinblastine and dacarbazine | 1L advanced | None |
Adcetris | CD30+ | + etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone | 1L advanced | Stage IIB with risk factors, Stage III or Stage IV |
Adcetris | CD30+ | Monotherapy | Consol. | Following autologous stem cell transplant (ASCT); At increased risk of relapse or progression |
Adcetris | CD30+ | Monotherapy | 3L+ | Following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option |
4 approvals for Hodgkin need no biomarker and apply whatever the result. All approvals for Hodgkin
See also
Label wording4
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) (see sections 4.2 and 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1).
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): 1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.